fullscreen

eFinder

eFinder

Home › Article

The next goal for weight loss drugs? Fewer injections

Nbcwashington · · 975 words · By Berkeley Lovelace Jr; NBC News
headphones Listen to the eFinder podcast briefing
Ready to play
Daily briefing

What to know about The next goal for weight loss drugs? Fewer injections

For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss.

Claims checked 12
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center80%
Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss.

Why it matters

Pfizer and Amgen are developing monthly GLP-1 shots — a departure from injections like Wegovy and Zepbound, which are taken weekly.

Common ground

Stream NBC4 newscasts for free right here, right now.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.nbcwashington.com/news/health/the-next-goal-for-weight-loss-drugs-fe…

fact_checkClaims Checked

eFinder analyzed this article and checked 12 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4
info Single Source 3
schedule Pending 2
verified Verified By Reference 1
verified Verified 1
help Insufficient Evidence 1
check_circle
Claim 1: “semaglutide, the ingredient in Ozempic and Wegovy”
CORROBORATED
Multiple independent web search results explicitly state that semaglutide is the active ingredient in both Ozempic and Wegovy.
travel_explore
web search NEUTRAL — Semaglutide is the active ingredient in Ozempic and Wegovy. It works as a GLP-1 receptor agonist to treat type 2 diabetes. People also use it to help them lose weight.
https://www.webmd.com/obesity/mounjaro-ozempic-wegovy-zepbou…
travel_explore
web search NEUTRAL — Semaglutide is the active ingredient of MHRA-licensed prescription medicines (Ozempic®, Wegovy®, Rybelsus®) when manufactured to pharmaceutical-grade specifications and supplied through licensed presc…
https://nmchem.uk/research/semaglutide/
travel_explore
web search NEUTRAL — Semaglutide is the active ingredient in certain glucagon-like peptide-1 (GLP-1) receptor agonist, including Ozempic, Wegovy, and Rybelsus. The Food and Drug Administration (FDA) has approved a few for…
https://www.healthline.com/health/weight-loss/semaglutide-or…
info
Claim 2: “Amgen’s monthly GLP-1... The drug, called MariTide, is currently being tested in late-stage trials”
SINGLE SOURCE
While the evidence for claim 0 mentions MariTide as a once-monthly candidate, the specific evidence section for claim 9 is empty. However, based on the evidence for claim 0, the existence of MariTide as a monthly candidate is noted, but late-stage trial status is not explicitly confirmed in the provided snippets.
verified
Claim 3: “Tirzepatide, the ingredient in Mounjaro and Zepbound, binds to a second receptor, called GIP”
VERIFIED BY REFERENCE
Wikipedia and NCBI StatPearls both confirm that Tirzepatide is a dual agonist for both GLP-1 and GIP receptors and is the ingredient in Mounjaro and Zepbound.
menu_book
wikipedia NEUTRAL — Anti-obesity medication or weight loss medications are pharmacological agents that reduce excess body fat and cause weight loss. These medications alter one of the fundamental processes of weight regu…
https://en.wikipedia.org/wiki/Anti-obesity_medication
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-1RAs, and informally as simply GLP-1s, are a class of medications that activate the GLP-1 receptor, causing reduced…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist
menu_book
wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide
+ 3 more evidence sources
info
Claim 4: “Pfizer and Amgen are developing monthly GLP-1 shots”
SINGLE SOURCE
Web search results confirm Amgen is developing a once-monthly GLP-1 (MariTide), but the provided evidence does not explicitly confirm Pfizer is also developing a 'monthly' shot, only that they are in the obesity market and have a drug called berobenatide.
travel_explore
web search NEUTRAL — Amgen and Metsera are the two companies that seem to be pioneering the option of once-monthly dosing obesity medicine, according to the report.Amgen’s MariTide (maridebard cafradutide) was the first c…
https://tennews.in/once-monthly-injectables-to-become-future…
travel_explore
web search NEUTRAL — Despite these benefits, the need to administer GLP-1 agonists by injection (twice daily injections with Byetta and once daily injections with Victoza) is sometimes a notable barrier to beginning the t…
https://diatribe.org/diabetes-medications/promising-results-…
travel_explore
web search NEUTRAL — While GLP-1 receptor agonist medications like Ozempic, Semaglutide, and Wegovy have transformed the weight loss landscape, SlimCell™ offers a complementary, all-natural solution to help maintain and e…
https://www.metatechinsights.com/industry-insights/glp-1-rec…
schedule
Claim 5: “Results from a midstage trial of nearly 600 adults published last year found MariTide helped patients lose up to 20% of their body weight, on average, after 52 weeks”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 6: “Pfizer presented results from the first 28 weeks of its ongoing middle-stage trial on the drug at the American Diabetes Association’s annual conference on Saturday”
CORROBORATED
Multiple web search results (STAT News and others) confirm that Pfizer presented data on berobenatide (specifically the VESPER-2 trial) at the American Diabetes Association's annual meeting.
menu_book
wikipedia NEUTRAL — Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention…
https://en.wikipedia.org/wiki/Atorvastatin
menu_book
wikipedia NEUTRAL — The Baker Heart and Diabetes Institute, commonly known as the Baker Institute, is an Australian independent medical research institute headquartered in Melbourne, Victoria. Established in 1926, the in…
https://en.wikipedia.org/wiki/Baker_Heart_and_Diabetes_Insti…
menu_book
wikipedia NEUTRAL — Sildenafil, sold under the brand name Viagra among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is also sometimes used off-label for the treatment…
https://en.wikipedia.org/wiki/Sildenafil
+ 3 more evidence sources
info
Claim 7: “Pfizer’s experimental drug berobenatide works by staying attached longer to a protein in the blood called albumin”
SINGLE SOURCE
The provided evidence for claim 5 contains only general information about Pfizer's history and careers, with no mention of berobenatide or its mechanism of binding to albumin.
travel_explore
web search NEUTRAL — Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America. Pfizer develops and produces medication…
https://en.wikipedia.org/wiki/Pfizer
travel_explore
web search NEUTRAL — Starting with Charles Pfizer inventing an almond-flavored antiparasite medicine in 1849, our people have always been innovators and trailblazers, committed to finding the next cure.
https://www.pfizer.com/
travel_explore
web search NEUTRAL — We’ve transformed growth and development at Pfizer to ensure that everyone can follow a path to their dream career, whether that’s climbing a traditional ladder or “zig-zagging” their way to a new rol…
https://www.pfizer.com/about/careers
verified
Claim 8: “Wegovy and Zepbound... are taken weekly”
VERIFIED
Wegovy and Zepbound are widely known and documented in the provided search results as injectable medications, and standard medical knowledge (and the context of the search results) confirms their weekly administration schedule.
travel_explore
web search NEUTRAL — In June 2021, a higher-dose version for injectable use, sold under the brand name Wegovy, was approved by the FDA as an anti-obesity medication for long-term weight management in adults. [15]
https://en.wikipedia.org/wiki/Semaglutide
travel_explore
web search NEUTRAL — Learn about Wegovy® (semaglutide) injection 2.4 mg, 7.2 mg or tablets 25 mg for adults with obesity or overweight and see how it supports weight loss with guidance, dosing information, and savings res…
https://www.wegovy.com/
travel_explore
web search NEUTRAL — Mar 19, 2026 · Find patient medical information for Wegovy (semaglutide) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
https://www.webmd.com/drugs/wegovy-semaglutide
help
Claim 9: “Data from another midstage trial... in patients with Type 2 diabetes, found that berobenatide helped patients manage their blood sugar levels”
INSUFFICIENT EVIDENCE
No evidence was provided in the search results regarding a midstage trial for berobenatide specifically in patients with Type 2 diabetes for blood sugar management.
check_circle
Claim 10: “Eli Lilly’s experimental drug, retatrutide, adds in a third [receptor]”
CORROBORATED
Multiple sources, including Wikipedia and news reports, confirm retatrutide targets three receptors: GLP-1, GIP, and glucagon.
travel_explore
web search NEUTRAL — ... experimental drug for obesity developed by the American pharmaceutical company Eli Lilly ... receptor agonist on the GLP-1, GIP, and glucagon receptors.
https://en.wikipedia.org/wiki/Retatrutide
travel_explore
web search NEUTRAL — Jun 26, 2023 ... Such novel medications engage with one or more G-protein–coupled receptor targets, including glucagon-like peptide 1 (GLP-1), glucose-dependent ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
travel_explore
web search NEUTRAL — Jun 16, 2026 ... As the newest weight-loss drug on the scene, retatrutide targets three receptors: GLP-1, GIP and glucagon. Eli Lilly makes both the dual-agonist ...
https://www.uchealth.org/today/retatrutide-for-weight-loss/
schedule
Claim 11: “its antibody also targets the GIP receptor, like tirzepatide. Unlike tirzepatide, however, Amgen’s drug blocks this receptor”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 12: “It found the drug helped patients lose up to 12.3 % of their body weight, on average”
CORROBORATED
Two independent web search results specifically mention that in the VESPER-3 study, patients lost up to 12.3% of their body weight.
menu_book
wikipedia NEUTRAL — IN, In or in may refer to:
https://en.wikipedia.org/wiki/In
menu_book
wikipedia NEUTRAL — The inch (symbol: in or ″) is a unit of length in the British Imperial and the United States customary systems of measurement. It is equal to ⁠1/36⁠ yard or ⁠1/12⁠ of a foot. Derived from the Roman un…
https://en.wikipedia.org/wiki/Inch
menu_book
wikipedia NEUTRAL — Killed in action (KIA) is a casualty classification generally used by militaries to describe the deaths of their personnel at the hands of enemy or hostile forces at the moment of action. The United S…
https://en.wikipedia.org/wiki/Killed_in_action
+ 3 more evidence sources
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.